Therapy Directory

Elranatamab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Elranatamab as a study intervention. Browse Elranatamab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Local indexed summaries

Local recruiting

The trial list below is retrieved from the live ClinicalTrials.gov search API for Elranatamab. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 30 matching trials for Elranatamab.

Indexed local directory records.

Top conditions

Multiple Myeloma 24 Multiple Myeloma (MM) 2 Refractory Multiple Myeloma 2 Relapse Multiple Myeloma 2 Relapsed Refractory Multiple Myeloma (RRMM) 2 AL Amyloidosis 1

Top sponsors

Pfizer 13 Massachusetts General Hospital 3 M.D. Anderson Cancer Center 2 AstraZeneca 1 Brigham and Women's Hospital 1 C4 Therapeutics, Inc. 1

Top locations

New York, New York 14 Boston, Massachusetts 11 Miami, Florida 9 Atlanta, Georgia 8 Deerfield Beach, Florida 6 Houston, Texas 6

Indexed official records

Open in full search

Conditions: Multiple Myeloma
Interventions: Elranatamab, Iberdomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Coral Gables, Florida • Deerfield Beach, Florida • Doral, Florida + 20 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Carfilzomib, Dexamethasone, Elotuzumab, Elranatamab, Pomalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 97
States / cities: Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more

Conditions: Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 14
States / cities: Fort Collins, Colorado • Greeley, Colorado • Longmont, Colorado + 7 more

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions: DC/MM Fusion Vaccine, Elranatamab, GM-CSF; Biological · Drug
Lead sponsor: David Avigan; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: AZD0305, Dexamethasone, Elranatamab, Pomalidomide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Duarte, California • Irvine, California • Atlanta, Georgia + 6 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Dexamethasone, Elranatamab, Pomalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 11
States / cities: Clovis, California • Fresno, California • Fort Collins, Colorado + 7 more

Conditions: Multiple Myeloma (MM), Multiple Myeloma, Newly Diagnosed
Interventions: Daratumumab, Elranatamab, Lenalidomide, autologous stem cell transplantation; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more

Conditions: Multiple Myeloma (MM)
Interventions: Cemsidomide, Elranatamab; Drug · Biological
Lead sponsor: C4 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Gilbert, Arizona • Santa Monica, California • Tampa, Florida + 13 more

Conditions: Elranatamab, Extramedullary Disease in Multiple Myeloma, PMD, Paramedullary Disease, Phase 2, Radiotherapy-Induced Immune Priming, Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Elranatamab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Relapsed Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Isatuximab SC, Isatuximab SC-OBDS, elranatamab; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Cyclophosphamide, Elranatamab-bcmm; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

About this Elranatamab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Elranatamab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Elranatamab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Elranatamab clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Elranatamab in R/R Multiple Myeloma

ELISA in Relapsed/Refractory MM

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

About this Elranatamab clinical trials directory page